|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1399 New York Avenue NW |
Address2 | Suite 600 |
| City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401049961-12
|
||||||||
|
6. House ID# 422720000
|
||||||||
| TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Paul Ehrlich |
Date | 7/20/2016 8:28:43 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 4974 & S. 2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017;
S. 2804, Energy and Water Development and Related Agencies Appropriations Act, 2017 (and related House bill not yet introduced);
P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029);
Other Labor, Health and Human Services Appropriations (No Bills Introduced);
Potential Amendments to Appropriations Bills (not introduced);
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Michael |
Boyd |
|
|
|
Stephen |
Scango |
|
|
|
Daniel |
Bachner |
|
General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015;
H.R. 1537 & S. 1878, Advancing Hope Act of 2015;
S. 632, STRONG Patents Act of 2015;
H.R. 9, Innovation Act;
S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016;
H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013;
H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015;
S. 2615, Increasing Competition in Pharmaceuticals Act;
Proposals/Initiatives related to international intellectual property protection;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Michael |
Boyd |
|
|
|
Daniel |
Bachner |
|
General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 6, 21st Century Cures Act
S. 2700, FDA and NIH Workforce Authorities Modernization Act;
H.R. 3381, Childhood Cancer STAR Act;
Discussions to clarify or reform the 340B program;
Biologics Price Competition and Innovation Act;
H.R. 1101 & S. 1287, Viral Hepatitis Testing Act;
Public Law 111-148, The Patient Protection and Affordable Care Act;
H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015;
H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015;
H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015;
Proposals to address prescription drug abuse;
Implementation of The Prescription Drug User Fee Act (PDUFA);
Implementation of The Biosimilars User Fee Act (BsUFA);
Public Law 113-54, Drug Quality & Security Act;
H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies;
H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015;
H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015;
S. 524, Comprehensive Addiction and Recovery Act of 2016;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Daniel |
Bachner |
|
General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons |
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Policies to enhance patient access to medicines in Medicaid;
Policies to enhance patient access to medicines in Medicare;
H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015;
H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act;
H.R. 2005 & S. 1083, Medicare Drug Savings Act;
H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015;
Medicare payment proposals;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Michael |
Boyd |
|
|
|
Daniel |
Bachner |
|
General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons |
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 880, American Research and Competitiveness Act of 2015;
H.R. 1430, Permanent CFC Look-Through Act;
H.R. 415 & S. 198, Stop Corporate Inversions Act;
S. 1946, Tax Relief Extension Act of 2015;
H.R. 1, Tax Reform Act of 2014;
Administrations Tax Reform and 2017 Budget Proposals;
Senate and House Committee Tax Reform Proposals;
Puerto Rican Economy and Debt Relief Proposals (no bills introduced);
Reps. Boustany and Neal: "Innovation Promotion Act" Discussion Draft
Proposals to reform domestic and international tax structures (no bills introduced);
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
John |
Ford |
|
|
|
Daniel |
Bachner |
|
General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trans-Atlantic Trade and Investment Partnership;
Trans-Pacific Partnership Agreement;
Trade Promotion Authority;
Columbia-America Free Trade Agreement;
Saudi Arabia Cancellation of Tender Issue;
Japan Biannual Re-Pricing Issue;
Plan COLOMBIA;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Natl Security Council (NSC), Commerce - Dept of (DOC), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrew |
Kaplan |
|
|
|
Michael |
Boyd |
|
|
|
Steven |
Scango |
|
|
|
Heather |
Strawn |
|
|
|
John |
Ford |
|
|
|
Daniel |
Bachner |
|
General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |